Veradermics, Inc (MANE) stock
MANENYSEPharmaceutical PreparationsFiscal year ends December 31
$124.86−0.78 (-0.62%)
Close on Nov 18, 2026Market cap $5.22BP/E –Yield –
Veradermics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2025 it was -$71.63M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$71.63M | – |
| FY2024 | Dec 31, 2024 | -$23.69M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$14.51M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.17M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.64M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.34M | – |
See a number that looks wrong?